UK Markets closed

Paratek Pharmaceuticals, Inc. (PRTK)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.9100+0.1300 (+2.72%)
At close: 4:00PM EDT
4.8500 -0.06 (-1.22%)
After hours: 04:15PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5N/A
Enterprise value 3N/A
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7N/A

Trading information

Stock price history

Beta (5Y monthly) 1.55
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 311.2400
52-week low 34.5100
50-day moving average 34.9486
200-day moving average 36.5715

Share statistics

Avg vol (3-month) 3398.51k
Avg vol (10-day) 3248.05k
Shares outstanding 546.92M
Implied shares outstanding 6N/A
Float 840.49M
% held by insiders 18.57%
% held by institutions 155.50%
Shares short (14 Jun 2021) 44.39M
Short ratio (14 Jun 2021) 47.32
Short % of float (14 Jun 2021) 49.69%
Short % of shares outstanding (14 Jun 2021) 49.36%
Shares short (prior month 13 May 2021) 44.26M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 328 Oct 2014
Ex-dividend date 430 Oct 2014
Last split factor 21:12
Last split date 330 Oct 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021

Profitability

Profit margin -157.44%
Operating margin (ttm)-119.33%

Management effectiveness

Return on assets (ttm)-21.04%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)55.43M
Revenue per share (ttm)1.22
Quarterly revenue growth (yoy)107.40%
Gross profit (ttm)14.35M
EBITDA -65.53M
Net income avi to common (ttm)-87.27M
Diluted EPS (ttm)-2.1850
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)103.45M
Total cash per share (mrq)2.2
Total debt (mrq)252.95M
Total debt/equity (mrq)N/A
Current ratio (mrq)6.18
Book value per share (mrq)-2.20

Cash flow statement

Operating cash flow (ttm)-94.62M
Levered free cash flow (ttm)-49.5M